Premenstrual Syndrome Treatment Market Size, Trends, Growth and Outlook Report 2025-2033

Market Overview
The global Premenstrual Syndrome Treatment Market size reached USD 1,443 Million in 2024. It is expected to grow to USD 1,920 Million by 2033, reflecting a CAGR of 3.2% during the forecast period 2025-2033. Key growth drivers include the rising focus on precision medicine, increased healthcare spending, and growing female workforce participation, which collectively enhance access to and demand for effective PMS treatment solutions. 

Study Assumption Years
• Base Year: 2024
• Historical Years: 2019-2024
• Forecast Period: 2025-2033

Premenstrual Syndrome Treatment Market Key Takeaways
• The market size was USD 1,443 Million in 2024.
• The compound annual growth rate (CAGR) during 2025-2033 is 3.2%.
• The forecast period covered is 2025-2033.
• The market growth is strongly driven by rising demand for precision medicine, improving treatment outcomes and efficiency.
• Increasing healthcare expenditure enhances access to a wider range of PMS treatments globally.
• Expansion of the female workforce highlights economic concerns related to PMS, driving demand for effective therapies.
• North America holds the largest market share due to a strong healthcare infrastructure and high medication affordability.

Sample Request Link: https://www.imarcgroup.com/premenstrual-syndrome-treatment-market/requestsample

Market Growth Factors
The PMS treatment market is driven by the increased emphasis on precision medicine, and the precision medicine market was valued at US$ 75.2 Billion globally in 2023. Precision medicine provides patient-specific treatment based on genetic, hormonal, and symptomatic factors. This leads to better PMS treatments with less side effects, reduces the trial and error needed for finding the right treatment and increases the health outcomes of patients leading to the growth of the market.

The expansion of healthcare spending, with an associated increase in access to PMS testing and treatment, is expected to benefit the market. Healthcare spending as a percentage of GDP (indicating access to care) is expected to grow from 17.3% in 2022 to 19.7% in 2032, increasing access to pharmacological and non-pharmacological care. This high level of spending allows the research and development of new PMS drugs and therapies.

The growing workforce participation of women (49% of the global workforce in 2023) has also driven investment in PMS treatments and workplace wellness programs. As PMS symptoms negatively affect productivity and employee attendance in the workplace, such programs are helping to increase awareness, treatment accessibility, and flexible policies regarding symptomatic days, thus driving growth in PMS treatments.

Market Segmentation

Breakup by Drug Type:
• Analgesics: Represent the largest segment as they provide quick relief from physical PMS symptoms like abdominal pain and headaches, making them the preferred choice for immediate comfort.
• Antidepressants
• Oral Contraceptives and Ovarian Suppression Agents
• Others

Breakup by Type:
• Prescription
• Over-the-Counter: Hold the largest market share, offering accessible solutions such as pain relievers, diuretics, and supplements without a prescription. Their availability in pharmacies, retail, and online facilitates ease of symptom management.

Breakup by Distribution Channel:
• Hospital Pharmacies
• Drug Stores and Retail Pharmacies: Lead the segment as they provide diverse OTC options and quick accessibility for women seeking PMS relief.
• Online Stores

Regional Insights
North America dominates the premenstrual syndrome treatment market due to its robust healthcare infrastructure and strong economy, which enhance medication affordability. For instance, Canadian health care spending reached $344 billion in 2023. This region also experiences a high prevalence of PMS, increasing demand for effective treatments and specialized healthcare services dedicated to women's health.

Recent Developments & News
• On September 12, 2023, Vistagen announced positive results from an exploratory phase 2A study of PH80 for acute management of premenstrual dysphoric disorder (PMDD), including mood and physical symptoms.
• In 2024, Samphire Neuroscience secured $2.3 million in funding to develop neurotechnology wearables to address PMS and period pain.

Key Players
• AbbVie Inc.
• BASF SE
• Bayer AG
• Dr. Reddy’s Laboratories Ltd
• Eli Lilly and Company
• GlaxoSmithKline Plc.
• H. Lundbeck A/S
• Pfizer Inc.
• SHIONOGI & Co. Ltd.

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

Request for Customization: https://www.imarcgroup.com/request?type=report&id=4284&flag=E

About Us
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No: (D) +91 120 433 0800
United States: +1-201971-6302